Introduction
Gram negative bacteria (GNB) infections are common in clinics. Sepsis and subsequent endotoxin shock have been increasing in recent years. The situation is explained by an increased population of patients receiving anti-cancer chemotherapy, immunosuppressive medicine after organ transplantation and invasive surgical procedures. These patients are classified as a high-risk group susceptible to sepsis (1) (2) (3) (4) . The death rate of GNB infection patients will be significant decreased if a prophylaxis therapy is clinically available.
Bactericidal/permeability-increasing protein (BPI) is a 55 kDa cationic bactericidal protein, present in many mammalian polymorphonuclear neutrophil leukocytes, such as human, bovine, pig, etc. (5) . BPI has the effect of neutralizing endotoxin and directly killing GNB, but has no adverse effect on eukaryotic cells (6, 7) . The phase II/III trial of rBPI 23 and rBPI 21 demonstrated that administration of rBPI has effect on GNB infected patient (8, 9) . But rBPI 55 and rBPI 21 have low efficacy and short half-life (less than 45 minutes) in vivo, and administration of them in large dosage is very expensive (10, 11) . It is difficult to use in clinical therapy. In order to improve the activity and prolong the half-life of rBPI, we designed and expressed a recombinant human BPI 23 -Fcγ1 fusion protein (12) . It was demonstrated that BPI 23 -Fcγ1 fusion protein has the effect of neutralizing endotoxin, directly killing GNB (including some drug-resistant GNB), opsonization, as well as prolonged half-life in vivo which protect the mice from minimal lethal dose (MLD) E. coli infection (13) . Based on the above study, the protective efficacy of chimeric BPI 23 -Fcγ1 gene delivery mediated by rAAV2 against lethal E. coli infection in the gene-transferred mice was studied. At the 2 ND week of gene delivery, BPI 23 -Fcγ1 fusion protein was expressed and secreted into blood circulation in rAAV2-BPI 23 -Fcγ1 gene transferred mice. After MLD E. coli and LPS challenge, the survival rate of rAAV2-BPI 23 -Fcγ1 gene transferred mice (35%-40%) was significantly higher than that of control mice (0%-6.7%) (14) .
In this study, we established immuno-compromised mice model to simulate high-risk patients. We tried to compare the protection of immuno-compromised mice with immunocompetent mice from lethal Klebsiella pneumonia infection by transferring chimeric BPI 23 -Fcγ1 gene through rAAV2 vector, which will help us to infer whether transfer of the rAAV2-BPI 23 -Fcγ1 can protect clinical high-risk patients from GNB infection.
Materials and Methods
Immuno-comprised mice model BALB/c mice (5-6 weeks, with weight of 16 ± 2 g) provided by Laboratory Animal Center, Military Academy of Medical Sciences (China) were divided into two groups. Group 1 (n = 5) were injected with hydrocortisone (0.2 mg/200 l/mouse, NO 04050910, purchased from Jinyao Co., Tianjin, China) and cyclophosphamide (1 mg/200 l/mice, NO 0502221 Hengrui Co., Jiangsu, China) every second day for total three times (15, 16) as immuno-compromised mouse. Group 2 (n = 5) were injected with only PBS as immunocompetent mice. At the 8th day after first injection, the body weight, spleen weight and spleen/body ratio were recorded and lymphocyte function was analyzed.
The analysis of T cell subsets by flow cytometry
Peripheral blood (100 l each mouse) was incubated with 10 l CD3-PE monoclonal antibody (Biotech Company), CD4-FITC or CD8-FITC monoclonal antibody (Biotech Company), mouse IgG isotype control (Biotech Company) at room temperature for 20 min. Then 2 ml RBC-lysing solution was added into each tube. Five minutes later, after centrifuged at 1000 rpm for 10 minutes, the pellet was resuspended into 0.5 ml of cold PBS for flow cytometry.
Lymphocyte proliferation
Mice were killed and single-cell suspensions of splenocytes were prepared. Cells were resuspended as 5 × 10 6 /ml in RPMI 1640 (Hyclone), 10% fetal calf serum, 2 mmol/L L-glutamine, 50 pg/ml streptomycin, and 100 U/ml penicillin. Cells were incubated in 96-well plate. Negative control well contains 5 l RPMI 1640 medium only, while positive control wells contained 5 l LPS (100 g/ml) and 5 l ConA (100 g/ml). The cells were cultured at 37°C with 5% CO 2 for 48 h. Then 15 l MTT (5 mg/ml, Sigma) was added and then incubated for another 4 hours. The formazan crystals were dissolved with DMSO solution (Sigma) and the absorption was determined by an ELISA reader at 570 nm. A stimulation index (SI) was used to evaluate lymphocyte proliferation. The SI of T lymphocyte was employed to define the ratio of OD 570 mean value of the ConA stimulated cells to that of the control (unstimulated). The SI of B lymphocyte was employed to define the ratio of OD 570 mean value of the LPS stimulated cells to that of the control (unstimulated).
Phagocyte assay
Mouse of each group was intraperitoneally injected with 0.5 ml staphylococcus solution (3 × 10 9 /ml). Forty-eight hours later, a second intraperitoneal injection of 1 ml yeast solution was administered. Fifteen minutes later, celiac liquid was aspirated for Wright's stain and microscopy. Percentage of phagocytes and phagocyte index were applied to evaluate phagocyte function.
Minimal lethal dose of Klebsiella pneumonia to immunocompetent mice or immuno-compromised mice
Klebsiella pneumonia (ATCC700603), provided by Beijing Tiantan Biological Products Co., Ltd. was diluted into 5  10 6 CFU/ml, 2  10 6 CFU/ml, 1  10 6 CFU/ml and 2  10 One week after these injections, the mice in test group were given immuno-suppressive drugs. By the end of the 2nd week, the immuno-compromised mice were challenged with MLD of Klebsiella pneumonia (1 × 10 5 CFU/mouse) and the mice in control group were challenged with MLD Klebsiella pneumoni (5 × 10 5 CFU/mouse) respectively, and then the mortality was recorded in 72 h.
Blood cultivation and colony counting
Blood samples of immuno-compromised mice were collected from orbital bulb at 6, 9, 12 and 18 hours after MLD Klebsiella pneumonia challenge. Serum was diluted (1:10) by normal saline (NS) and then dilution sample (50 l) was inoculated on Luria-Bertani media and followed by incubation at 37°C for 16 h. Livers and spleens of the test animals were collected and triturated by steel wire screen (200 meshes). Then 50 l homogenate (diluted by NS 1:100) was inoculated on Luria-Bertani media and incubated at 37°C for 16 hours. Bacterial colony formation units (CFU) were then counted.
Limulus amebocyte lysate (LAL) assay
Serum sample was diluted (1:10) in pyrogen-free water and LAL assay was performed according to the procedures recommended by Amebocyte Lysate Kit (YiHua Co., Shanghai, China).
Proinflammatory cytokine assay
Interleukin-1 (IL-1) and tumour necrosis factor- (TNF-) in serum sample was detected by ELISA according to procedures from manufacturer (R&D Systems Inc., Minneapolis, MN, USA).
Statistical analysis
Data were represented as mean ± standard deviation (SD) of more than three separate replicate experiments. Chi-square test was performed for survival rate comparison. Differences among groups were analysed by independent-samples t test. ( = 0.05, two-sided). The value of p < 0.05 were considered to be statistically significant.
Results

The physical profile of immuno-compromised mice
There was no significant difference on body weight between the two groups. The spleen weight and spleen/body weight ratio of mice in immuno-compromised group are lower than that of mice in immunocompetent group (Table 1) . Short- term administration of immunosuppressive drugs had little impact on the body weight of mice but significantly decreased spleen mass. The immunosuppressive drugs also inhibited lymphocyte response to Con A and LPS as shown by poor response of T lymphocytes and B lymphocytes (Table 2) . Likewise, the percentage of phagocyte and phagocytic index of immuno-compromised mice in test group were significant lower than that of mice in control group ( Table 2 ). The total number and percentage of the CD3 + /CD4 + /CD8 + T lymphocytes of immuno-compromised mice in test group were much lower than that of mice in the control group (p < 0.05) (Figure 1 ). These results demonstrated that the animal model of immuno-compromised mice well simulated immunosuppressive situation in vivo.
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MLD Klebsiella pneumonia in immunocompetent and immunocompromised mice
The mortality of each group in immunocompetent and immuno-compromised mice after challenge with different doses of Klebsiella pneumonia was shown in Table 3 . When immunocompetent mice were infected with Klebsiella pneumonia, all animals in the 1st and the 2nd group died in 36 h. The mortality of the 3rd and 4th group was 90% and 40% respectively in 72 h. Therefore, the MLD Klebsiella pneumonia to immunocompetent mice was defined as 5 × 10 5 CFU/mouse. When Klebsiella pneumonia infected immunocompromised mice, animals of the 1st and 2nd group died in 48 h. The mortality of the 3rd and the 4th group was 95% and 55% respectively in 72 h. Therefore, the MLD Klebsiella pneumonia to immuno-compromised mice was defined as 1 × 10 5 CFU/mouse. It demonstrated that the minimal lethal dose of Klebsiella pneumonia to immunocompetent mice was 5-fold higher than that to immuno-compromised mice. (5 ×  10 5 CFU/0.5 ml). The survival rate was recorded in 72 h after bacterial injection. Results were shown in Figure 2 . The survival rate of rAAV2-BPI23-Fcγ1 gene transferred immunocompetent mice (40.0%, n = 45) was significant higher than that of rAAV2-Null (6.7%, n = 30) and rAAV2-EGFP transferred immunocompetent mice (6.7%, n = 45) ( 2 = 13.97, p < 0.01). While the survival rate of rAAV2-BPI23-Fcγ1 gene transferred immuno-compromised mice (44.4%, n = 45) was significant higher than that of rAAV2-Null (3.3%, n = 30) and rAAV2-EGFP transferred immuno-compromised mice (4.4%, n = 45) ( 2 = 19.50, p < 0.01).
Protection of rAAV2-BPI23-Fcγ1 gene transferred mice from MLD Klebsiella pneumonia infection rAAV2-BPI23-Fcγ1 gene transferred immunocompetent mouse was challenged by MLD Klebsiella pneumonia
These results indicated that rAAV2-BPI23-Fcγ1 gene transferred mice were resistant to the MLD of Klebsiella pneumonia infection. It suggested that BPI23-Fcγ1 gene delivery has potential in preventing GNB infection of clinical high-risk patients.
Biological activity of BPI23-Fcγ1 protein in immunocompromised mice
For further evaluation of biological activity of BPI23-Fcγ1 rAAV2-BPI23-Fc1 gene in transferred immuno-compromised mice killed Klebsiella pneumonia and so offered resistance to MLD Klebsiella pneumonia infection. The level of endotoxin and proinflammatory cytokine (IL-1, TNF-) in the serum of BPI23-Fcγ1 gene transferred immuno-compromised mice was significantly lower than that of EGFP transferred mice at the 9th, 12th and 18th hour after bacterial challenge (p < 0.01). The level of endotoxin and proinflammatory cytokine in the serum of both groups of mice reached its peak at the 12th hour ( Figures 4A, 4B, 4C ). BPI23-Fcγ1 gene transferred immuno-compromised mice were resistant to endotoxin shock caused by MLD Klebsiella pneumonia infection through the mechanisms of killing Klebsiella pneumonia, neutralizing endotoxin and inhibiting production of proinflammatory cytokines.
Discussion
The high-risk individuals of GNB infection are those with poor immunity resulted from chemotherapy, autoimmune disease, or immunosuppression treatment after transplantation (17, 18) . However, no prophylactic method for bacterial infection occurred is available. Amazing progress in gene therapy and transfer products applied in clinical management of cancer, monogenic diseases, autoimmune diseases, HIV and bacterial infection. Viral delivery systems have been widely used in gene therapy protocols because of its high efficiency (19) (20) (21) (22) . Gutless viral vector is safe with low oncogenicity, poor immunogenicity, and does not exaggerate the inflammatory reaction (23) (24) (25) . rAAV2 has been widely used as a gene delivery vehicle in pre-and early clinical trials. BPI23-Fcγ1 fusion protein has the effectiveness of killing GNB, neutralizing endotoxin, fixing complement and has a long half-life span. So we selected BPI23-Fcγ1 gene as the target gene in our test.
We prepared rAAV2-BPI23-Fc1 with a high viral load, which successfully mediated BPI23-Fc1 gene transfer and expression in mouse muscle cells. In this study, we developed immuno-compromised mice model to simulate high-risk individuals of GNB infection in clinic settings. We studied the resistance of both immuno-compromised and immunocompetent mice that were transfected with rAAV2-BPI23-Fcγ1 against MLD of Klebsiella pneumonia. The MLD of Klebsiella pneumonia identified in immunocompetent mice (5 × 10 5 CFU/mouse) was 5-fold higher than that in immuno-compromised mice (1 × 10 5 CFU/mouse). The survival rate of both BPI23-Fcγ1 transferred immunocompetent mice (40.4%) and immuno-compromised mice (44.4%) were significant higher than that in control groups (6.7% and 3.3%-4.4%) respectively after challenge with MLD Klebsiella pneumonia. It suggested that transferring BPI23-Fcγ1 gene provides protection against GNB infection in both immuno-compromised and immunocompetent mice. After Klebsiella pneumonia infection, the counting of bacteria in serum, liver and spleen as well as the level of endotoxin and pro-inflammatory cytokines in serum of rAAV2-BPI23-Fcγ1 gene transferred immuno-compromised mice decreased, while the survival rate increased markedly. These results prove that anti-bacteria gene transferring offers resistance to GNB infection in immuno-compromised mice. It suggests that rAAV2-BPI23-Fcγ1 gene delivery has potential clinical application especially in high-risk patients exposing to GNB infection. 
